RxDoctor Payments Data

Xiaoming Dong, MD

Neurology · Golden Valley, MNNPI 1265488340

Payments from drug & device makers

$47,461in general payments, 2019–2025

Across 102 payments — averaging $465.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$31K
  • Eisai Inc.$15K
  • Biogen$906
  • Takeda Pharmaceuticals U.S.A., Inc.$59
  • Boston Scientific$51
  • Teva Pharmaceuticals USA, Inc.$44
  • plus $315 from 14 others

What the payments were for

  • Consulting fees$8,51618%
  • Speaking & faculty fees$31,82967%
  • Travel & lodging$6,03513%
  • Food & beverage$1,0382%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,461 in reported general payments places this provider in the 80th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$207,200
Medicare patients
297
Services billed
50,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Memantine Hcl289$10,394
Donepezil Hcl558$9,476
Levetiracetam180$7,128
Carbidopa-Levodopa ErCarbidopa/Levodopa97$6,384
Carbidopa-LevodopaCarbidopa/Levodopa140$4,380
Lacosamide25$3,925
Carbamazepine ErCarbamazepine40$3,347
Lamotrigine33$2,960
Sumatriptan Succinate11$2,899
Gabapentin168$2,826
Azathioprine21$2,043
Pregabalin50$1,427
RivastigmineRivastigmine Tartrate16$1,258
Quetiapine Fumarate94$1,247
Primidone23$1,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$31,478$51028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 434 neurology providers in Minnesota.

Other neurology in Golden Valley

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →